DOT1L and leukemia: Despite the promising mechanism, clinical trials of DOT1L inhibitors as monotherapy have shown limited efficacy, particularly in achieving durable remissions, likely due to the redundancy of oncogenic pathways in KMT2Ar leukemias [42].